ADMA Biologics Inc (ADMA)vsVertex Pharmaceuticals Inc (VRTX)
ADMA
ADMA Biologics Inc
$13.19
+0.38%
HEALTHCARE · Cap: $2.93B
VRTX
Vertex Pharmaceuticals Inc
$542.62
-0.81%
HEALTHCARE · Cap: $141.65B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 2325% more annual revenue ($12.59B vs $519.15M). ADMA leads profitability with a 35.1% profit margin vs 35.0%. ADMA trades at a lower P/E of 17.1x. ADMA earns a higher WallStSmart Score of 64/100 (C+).
ADMA
Buy64
out of 100
Grade: C+
VRTX
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ADMA.
Margin of Safety
+42.4%
Fair Value
$949.93
Current Price
$542.62
$407.31 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 42 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Safe zone — low bankruptcy risk
Attractively priced relative to earnings
Earnings expanding 46.7% YoY
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Areas to Watch
No major concerns identified
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ADMA
The strongest argument for ADMA centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 35.1% and operating margin at 44.9%.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : ADMA
No major red flags identified for ADMA, but monitor valuation.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
ADMA carries more volatility with a beta of 0.66 — expect wider price swings.
VRTX is growing revenue faster at 12.5% — sustainability is the question.
VRTX generates stronger free cash flow (546M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ADMA scores higher overall (64/100 vs 62/100), backed by strong 35.1% margins. VRTX offers better value entry with a 42.4% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ADMA Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures and markets plasma-derived biological products specialized for the treatment of immunodeficiencies and infectious diseases in the United States. The company is headquartered in Ramsey, New Jersey.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?